


News, current issues

- News: Pharmacists protesting over special tax >>
- News: Staff of healthcare institutions performing beyond expectations >>
- News: Hungarian healthcare to level up? Government issues telemedicine decree >>


Macro approach to financing healthcare and medicinal products

Balance of the Health Insurance Fund, February 2020



Source: Healthware analysis based on NHIFA data

Decision-making index, February 2020



Methodology

Product offering

Survey of references, meta – analysis

We collect the available information, evidence in related articles, directives, studies, research.

As the first step of systematic research of the scientific literature we define the relevant keywords. Then we present the evidence charts, it is followed by organization and comparative analysis.


Meta – analysis

We are able to make an exact summary of the results with statistical methods, which is based on the systematic research of scientific literature that led to compiling the parameters of evidence charts.

More details: [link](#)


Dynamics of the sales/circulation of prescription-only-medicine

Pharmacy DOT turnover



Source: Healthware analysis based on NHIFA data

Pharmacy reimbursement turnover



Source: Healthware analysis based on NHIFA data




Changes to subsidized medicinal product categories, February 2020




Source: Healthware analysis based on NHIFA data

Market data

Toplists of reimbursement and number of patients, February 2020




Average number of medical sales reps



Source: NHIFA data, Healthware analysis

TOP 10 active substances by number of patients (thousand patients)



Analysis of the ongoing submission procedures - Case study


Our last [special edition](#) examines the new, typically innovative pharmaceutical technologies that have been submitted but do not yet make the final decision by the National Health Insurance Fund of Hungary (NHIFA) and Ministry of Human Capacities (MoHC). This special edition has been updated with the 9 month event since the [previous report](#). The previous marked in red are also represented to make the changes clear visible. The analysis focuses only on the technologies that passed the standard 90 days period and bases on the data published by the NHIFA on April 09, 2020. The validity of published data has not been investigated by Healthware.

During the NHIFA co-ordinated period, the financing structure for the technology will be determined on the basis of submitted and agreed HTA, BIA and medical considerations. The final decision is taken by a Committee coordinated by the Ministry. Actual timelines of ongoing procedures are the following:

- ◆ NHIFA made a preliminary decision on 7% of the normal submissions.
- ◆ The average procedure time of the analyzed products is 273 days in case of normal submission (min-max: 101 and 1155 days) and 224 days (min-max: 101 and 531 days) when simplified submission.
- ◆ The average procedure time of NHIFA is 342 days in case of normal submission (min-max: 62 and 600 days) and 174 days when simplified submission.
- ◆ The average procedure time of MoHC is 512 days in case of normal submission (min-max: 312 and 827 days).
- ◆ 54 brands are waiting for ministerial decision at the moment.

Typically the average waiting time is longer in case of products which claimed changes in legislation and which are innovative products with new mode of action (e.g. PCSK9 inhibitors, targeted oncology therapies, immunotherapies). The most frequent indications are the neoplastic diseases and within that the colitis ulcerosa and the non-small cell lung cancer.

For the whole analysis, please visit our [LinkedIn](#) site.



Number of indications, companies, brands and SKUs involved in submission procedures over 90